Overall asthma control: The relationship between current control and future risk  Eric D. Bateman, MD, Helen K. Reddel, MBBS, PhD, FRACP, Göran Eriksson, MB, PhD, Stefan Peterson, PhD, Ollie Östlund, PhD, Malcolm R. Sears, MB, FRACP, FRCPC, Christine Jenkins, MD, FRACP, Marc Humbert, MD, Roland Buhl, MD, Tim W. Harrison, MD, Santiago Quirce, MD, PhD, Paul M. O'Byrne, MB, FRCP(C)  Journal of Allergy and Clinical Immunology  Volume 125, Issue 3, Pages 600-608.e6 (March 2010) DOI: 10.1016/j.jaci.2009.11.033 Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Goals of asthma management. Journal of Allergy and Clinical Immunology 2010 125, 600-608.e6DOI: (10.1016/j.jaci.2009.11.033) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Proportion of patients with Controlled and Controlled/Partly Controlled asthma by week according to GINA criteria (A) and exacerbations (B), by week. Percentage of patients achieving Controlled (week with all 5 diary card subcriteria controlled and no severe exacerbations) and Controlled/Partly Controlled asthma (week with no exacerbation and ≤2 subcriteria uncontrolled) by week (A); with ≥1 exacerbation requiring medical intervention during the week (excluding peak expiratory flow) (B). Pooled data from higher maintenance dose ICS plus SABA,14,15 same maintenance dose ICS/LABA plus SABA,14,18 and higher maintenance dose ICS/LABA plus SABA.16,17∗P values refer to analyses at last week of treatment (end of treatment). BUD/FORM, budesonide/formoterol. Journal of Allergy and Clinical Immunology 2010 125, 600-608.e6DOI: (10.1016/j.jaci.2009.11.033) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Proportion of patients below each ACQ-5 cut-point level over time, randomized to budesonide/formoterol maintenance and reliever therapy (n = 963 patients with a baseline ACQ-5 value and at least 1 value on treatment) versus same maintenance dose ICS/LABA plus SABA (n = 984). Data from Rabe et al.18BUD/FORM, budesonide/formoterol. Journal of Allergy and Clinical Immunology 2010 125, 600-608.e6DOI: (10.1016/j.jaci.2009.11.033) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Proportion of patients below each ACQ-5 cut-point level over time, randomized to budesonide/formoterol maintenance and reliever therapy (n = 2173 patients with a baseline ACQ-5 value and at least 1 value on treatment) versus higher maintenance dose ICS/LABA plus SABA (n = 3246). Data from Kuna et alE4 and Bousquet et al.E5BUD/FORM, budesonide/formoterol. Journal of Allergy and Clinical Immunology 2010 125, 600-608.e6DOI: (10.1016/j.jaci.2009.11.033) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Future risk of exacerbations using ACQ-5 at randomization as a predictor. Mean number of exacerbations over time stratified by ACQ-5 at randomization. Data pooled from all patients randomized to budesonide/formoterol maintenance and reliever therapy or higher maintenance dose ICS/LABA plus SABA (n = 5480).E4,E5 ACQ-5 <0.50, n = 355; ACQ-5 ≥0.50–<0.75, n = 250; ACQ-5 ≥0.75–<1.00, n = 261; ACQ-5 ≥1.00–<1.25, n = 686; ACQ-5 ≥1.25–<1.50, n = 345; ACQ-5 ≥1.50, n = 3583. Journal of Allergy and Clinical Immunology 2010 125, 600-608.e6DOI: (10.1016/j.jaci.2009.11.033) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions